English
中文简体
中文繁体
Company
Overview
Board of Directors
Partnering
Technology
Glycan-specific Conjugation
Alphatecan
Bispecific Antibody
Subcutaneous Formulation
Single-domain Antibody
Publications
Pipeline
Overview
Envafolimab(KN035)
KN026
JSKN003
JSKN016
JSKN033
KN046
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
Company
Overview
Board of Directors
Partnering
Technology
Glycan-specific Conjugation
Alphatecan
Bispecific Antibody
Subcutaneous Formulation
Single-domain Antibody
Publications
Pipeline
Overview
Envafolimab(KN035)
KN026
JSKN003
JSKN016
JSKN033
KN046
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
English
中文简体
中文繁体
Investors
Information Disclosure
Listing Documents
Financial Reports
Announcements & Circulars
Company Presentation
ESG Reports
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
Announcements & Circulars
The announcement begins in December 2019
(1) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES; (2) PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS; (3) PROPOSED RE-APPOINTMENT OF AUDITORS; AND (4) NOTICE OF ANNUAL GENERAL MEETING
2022-05-10
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2022
2022-05-06
GRANT OF SHARE OPTIONS
2022-04-25
VOLUNTARY ANNOUNCEMENT - UPDATES ON CLINICAL DATA OF KN046 IN COMBINATION WITH KN026 FOR THE TREATMENT OF HER2-POSITIVE SOLID CANCER FOR PRESENTATION AT 2022 AACR ANNUAL MEETING
2022-04-11
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2022
2022-04-07
VOLUNTARY ANNOUNCEMENT - THE FIRST INTERIM ANALYSIS OF A PHASE III CLINICAL TRIAL OF KN046 SUCCESSFULLY REACHED PRESPECIFIED PFS ENDPOINT
2022-03-31
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2021
2022-03-29
Date of Board Meeting
2022-03-11
VOLUNTARY ANNOUNCEMENT - PRELIMINARY RESULTS OF PHASE II CLINICAL TRIAL OF KN046 IN COMBINATION WITH KN026 FOR THE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC HER2-POSITIVE SOLID CANCER ACCEPTED FOR E-POSTER PRESENTATION AT 2022 AACR ANNUAL MEETING
2022-03-09
Next Day Disclosure Return
2022-03-03
12
13
14
15
16
17
18
PREV
15/27
NEXT